# EDGAR Filing Document

**Accession Number:** 0001565832
**File Stem:** 0001213900-23-007440
**Filing Date:** 2023-2
**Character Count:** 7625
**Document Hash:** b944549749eb013c4e1cc4f228585071
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-007440.hdr.sgml**: 20230202

**ACCESSION NUMBER**: 0001213900-23-007440

**CONFORMED SUBMISSION TYPE**: 5

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230202

**DATE AS OF CHANGE**: 20230202

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** TRAVERSA SERGIO
- **CENTRAL INDEX KEY:** 0001565832

**FILING VALUES:**
- **FORM TYPE:** 5
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39082
- **FILM NUMBER:** 23582018

**MAIL ADDRESS:**
- **STREET 1:** 138 CANTERBURY LN
- **CITY:** BLUE BELL
- **STATE:** PA
- **ZIP:** 19422
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RELMADA THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001553643
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 455401931
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2222 PONCE DE LEON BLVD. 3RD FLOOR
- **CITY:** CORAL GABLES
- **STATE:** FL
- **ZIP:** 33134
- **BUSINESS PHONE:** 646 876 3459

**MAIL ADDRESS:**
- **STREET 1:** 2222 PONCE DE LEON BLVD. 3RD FLOOR
- **CITY:** CORAL GABLES
- **STATE:** FL
- **ZIP:** 33134

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CAMP NINE, INC.
- **DATE OF NAME CHANGE:** 20120706

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>TRAVERSA SERGIO<br><sub>(Last) (First) (Middle)</sub><br>C/O RELMADA THERAPEUTICS, INC.<br>2222 PONCE DE LEON BLVD, 3RD FLOOR<br><sub>(Street)</sub><br>CORAL GABLES, FL 33134<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2022-12-31 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>RELMADA THERAPEUTICS, INC. [ RLMD ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $16.00 | 2021-07-08 |  | G<sup>(1)</sup> | V |  | 4131 | <sup>(2)</sup> | 2022-07-10 | Common Stock | 4131 | $0 | 0 | D |  |
| Stock Option (right to buy) | $16.00 | 2021-07-08 |  | G<sup>(1)</sup> | V |  | 27123 | <sup>(3)</sup> | 2023-09-30 | Common Stock | 27123 | $0 | 6165 | D |  |
| Stock Option (right to buy) | $54.00 | 2021-07-08 |  | G<sup>(1)</sup> | V |  | 8231 | <sup>(4)</sup> | 2025-02-23 | Common Stock | 8231 | $0 | 3019 | D |  |
| Stock Option (right to buy) | $43.47 | 2021-07-08 |  | G<sup>(1)</sup> | V |  | 131250 | <sup>(5)</sup> | 2029-12-19 | Common Stock | 131250 | $0 | 218750 | D |  |
| Stock Option (right to buy) | $33.43 | 2021-07-08 |  | G<sup>(1)</sup> | V |  | 93750 | <sup>(6)</sup> | 2031-01-07 | Common Stock | 93750 | $0 | 162500 | D |  |
| Stock Option (right to buy) | $33.43 | 2021-07-08 |  | G<sup>(1)</sup> | V |  | 87500 | <sup>(7)</sup> | 2031-01-07 | Common Stock | 87500 | $0 | 162500 | D |  |

---

### Footnotes:

(1) Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust.

(2) The options were granted on July 10, 2012. 25% of the options vested upon the grant date and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in July 2016.

(3) The options were granted on September 30, 2013. 25% of the options vested upon the date of grant and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in September 2017.

(4) The options were granted on February 15, 2015. 6.25% of the options vested each quarter from the date of grant.

(5) The options were granted on December 19, 2019. 6.25% of the options vest each quarter from the date of grant.

(6) The options were granted on January 7, 2021. 6.25% of the options vest each quarter from the date of grant.

(7) The options were granted on January 7, 2021. 25% of the options vested one year from the grant date, and thereafter in equal quarterly increments of 6.25% over the following three years.

**Signature:** /s/ Sergio Traversa  
**Date:** 2023-02-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**